Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

July 3, 2020 updated by: Dr Shiva Shankar Bugude, Qassim University

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study

On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Unknown

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide.

AIMs & Objectives of the Study This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research.

This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

Primary Outcomes of the Study To understand the geographical distribution of the interventional studies after 11th of March 2020.

To understand the geographical distribution of the Observational studies after 11th of March 2020.

To understand the monthly Research study completion rate as per geographic distribution of the Research.

Secondary Outcomes of the Study To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.

To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.

To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

Methodology WHO-compliant registries will be explored for completed COVID-19 Research articles.

Inclusion Criteria Interventional studies in the WHO-compliant registries database which are registered and completed after 11th of March 2020 until 15th of August 2020.

Observational studies in the WHO-compliant registries database which are registered and completed after 11th of March 2020 until 15th of August 2020.

Exclusion Criteria Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.

Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.

The articles selected from the WHO-compliant registries database will be categorized as per following relevance:

Interventional Studies: Theses studies will be further categorized based on type of Intervention. Inteventional studies can be Drug, Diagnostic tests, Rehabilitation, Procedure, Device, Behavioral, Dietary supplement, Biological, Physiotherapy & Others types of Interventional study.

Observational Studies: Prospective and Retrospective Observational studies.

The Studies will be mapped according to the Country where the Research is completed and the type of Research.

Type of Variables studied in this Study 6 Continuous variables are studied in this Study Number of Interventional Studies (Continuous variable) Number of Observational Studies (Continuous variable) Number of Drug based Interventional Study (Continuous variable) Number of Diagnostic test based interventional study (Continuous variable) Number of Device based interventional study (Continuous variable) Monthly Research study completion rate (Continuous variable)

8 Categorical variables will be studies in this study Interventional Study (Categorical variable) Observational Study (Categorical variable) Developed country (Categorical variable) Developing country (Categorical variable) Under developed country (Categorical variable) Drug based Interventional Study (Categorical variable) Diagnostic test based interventional study (Categorical variable) Device based interventional study (Categorical variable)

Statistical Analysis Data analysis will be carried out using SPSS 22.00 (Stata Corp, College Station, TX, USA). The Data obtained will be analysed for the normal distribution. If the data follows normal distribution curve, Pearson Correlation statistical test will be used to assess the Correlation of categorical and continuous variables. If the data does not follow normal distribution curve, Spearman Correlation or Chi square statistical test will be used to assess the Correlation of Categorical and continuous variables. The p-value (significance level) of the correlation will be determined. If the p-value is <5%, then the correlation between variables analysed will be considered as significant.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
200

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

1 year and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects who are infected with COVID-19. Healthy Volunteers who respond to survey. Subjects who have recently recovered from COVID-19 infection.

Description

Inclusion Criteria:

Interventional studies in the WHO-compliant registries database which are registered and completed after 11th of March 2020 until 15th of August 2020.

Observational studies in the WHO-compliant registries database which are registered and completed after 11th of March 2020 until 15th of August 2020.

Exclusion Criteria:

Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.

Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Completed Interventional studies
Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
Drug: Convalescent Plasma Transfusion
Convalescent Plasma Transfusion to COVID-19 infected patients.
Drug: Hydroxychloroquine
Hydroxychloroquine administration to COVID-19 infected patients.
Drug: DAS181
DAS181 administration to COVID-19 infected patients.
Drug: Ivermectin
Ivermectin administration to COVID-19 infected patients.
Drug: Interferon Beta-1A
Interferon Beta-1A administration to COVID-19 infected patients.
Completed Observational studies
Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
Drug: Convalescent Plasma Transfusion
Convalescent Plasma Transfusion to COVID-19 infected patients.
Drug: Hydroxychloroquine
Hydroxychloroquine administration to COVID-19 infected patients.
Drug: DAS181
DAS181 administration to COVID-19 infected patients.
Drug: Ivermectin
Ivermectin administration to COVID-19 infected patients.
Drug: Interferon Beta-1A
Interferon Beta-1A administration to COVID-19 infected patients.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Geographical distribution of the interventional studies after 11th of March 2020.
Time Frame: 15th of August 2020
To understand the geographical distribution of the interventional studies after 11th of March 2020.
15th of August 2020
Geographical distribution of the Observational studies after 11th of March 2020.
Time Frame: 15th of August 2020
To understand the geographical distribution of the Observational studies after 11th of March 2020.
15th of August 2020
Monthly Research study completion rate as per geographic distribution of the Research.
Time Frame: 15th of August 2020
To understand the monthly Research study completion rate as per geographic distribution of the Research.
15th of August 2020

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Statistical correlation of the interventional studies Research with developed, developing and under developed countries.
Time Frame: 15th of August 2020
To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.
15th of August 2020
Statistical correlation of the observational studies Research with developed, developing and under developed countries.
Time Frame: 15th of August 2020
To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.
15th of August 2020
Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.
Time Frame: 15th of August 2020
To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.
15th of August 2020
Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.
Time Frame: 15th of August 2020
To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.
15th of August 2020
Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
Time Frame: 15th of August 2020
To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
15th of August 2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Qassim University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 25, 2020

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 15, 2020

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 20, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 3, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 7, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 7, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • COAHS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The Research data will be extracted from the WHO-compliant registry databases.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Convalescent Plasma Transfusion

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings